Sciex’s recently launched accurate mass instrument, the ZenoTOF 7600 system, offers novel ion fragmentation and increased sensitivity for life science research and biotherapeutic development.
The ZenoTOF 7600 System, recently launched by Sciex in June 2021, is a mass liquid chromatography–mass spectrometry/mass spectrometry (LC–MS/MS) instrument that includes both Zeno trap and electron activated dissociation (EAD) fragmentation.
This new system enables scientists to better identify, characterize, and quantify molecules by generating data that has been previously unattainable, Sciex stated in a company press release. These capabilities are expected to help solve real analytical challenges and advance the development of new precision diagnostics and biotherapeutics.
Zeno trap pulsing delivers up to twenty times more sensitivity than traditional orthogonal time-of-flight technology, while EAD fragmentation can derive novel structural information from diverse compound types. With EAD fragmentation, the system can fully characterize individual lipids from a single spectrum, which can enable the discovery of novel lipid markers for cancer and inflammatory disease. EAD fragmentation also allows biopharma scientists to precisely detect and quantify protein glycosylation patterns and differentiate isomeric amino acids, which are both critical for ensuring that therapies are safe and do not produce adverse reactions.
Additionally, when compared to prior products, this new LC–MS/MS system can quantify up to 40% more proteins and analyze biobank samples five times faster, Sciex stated in the press release.
Source: Sciex
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.